Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

Curaleaf has launched a hostile takeover bid for Aurora Cannabis (ACB) at $4 per share, representing a 45% premium to the undisturbed trading price. The offer consists of 0.34 Curaleaf shares plus $0.75 in cash per ACB share, capped at $5 per share total consideration.

Aurora's board confirmed it will review the unsolicited proposal but issued immediate pushback, citing concerns over the financing structure and the $5 price ceiling. The acquisition rationale centers on Aurora's medical marijuana operations, which carry higher margins than the broader cannabis retail business.

Hostile takeovers in the cannabis sector face significant headwinds historically, with most failing to close due to board resistance and regulatory complexity. The bid comes as consolidation pressure mounts across the industry, driven by ongoing cash burn and compressed valuations.

The cash-and-stock structure shifts shareholder value depending on Curaleaf's share price movement, creating uncertainty around final consideration. Aurora shareholders face a decision between tendering into an uncertain outcome and betting on the board's ability to secure better terms or remain independent.